StockData
Pfizer Inc logo

Pfizer Inc

PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3053% above fair value
$30.52+0.57 (+1.90%)

Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%

Pfizer Braftovi + Mektovi (encorafenib / binimetinib by Quarter

Braftovi + Mektovi (encorafenib / binimetinib — BRAF+ melanoma/CRC/NSCLC) — International reported YoY (%) (%)

QuarterlyAnnual

Pfizer Braftovi + Mektovi (encorafenib / binimetinib: 54.0% in Q2 2026, down 6.0 pts from a year earlier.

Latest, Q2 2026
54.0%
Period ended Jun 28, 2026
Change on a year earlier
-6.0 pts
60.0% in Q2 2025
History
8 quarters
Since Q1 2024
Sources
8
Documents cited below

Where the Q2 2026 figure comes from

“|| Braftovi/Mektovi | 223 | 182 | 23% | 23% | 208 | 171 | 21% | 16 | 10 | 54% | 48%”

Source: Form 8-K (Earnings / Guidance Release) (pfe-6282026xex99.htm, filed 2026-08-04) ↗

Reported in Form 8-K Revenue Tables.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedBraftovi + Mektovi (encorafenib / binimetinib — BRAF+ melanoma/CRC/NSCLC) — International reported YoY (%) (%)Year on yearSource
Q2 2026Jun 28, 202654.0%-6.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-6282026xex99.htm, filed 2026-08-04) ↗
Q1 2026Mar 29, 202684.0%+31.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-3292026xex99.htm, filed 2026-05-05) ↗
Q4 2025Dec 31, 202599.0%–Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
Q3 2025Sep 28, 202552.0%-16.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-09282025xex99.htm, filed 2025-11-04) ↗
Q2 2025Jun 29, 202560.0%–Form 8-K (Earnings / Guidance Release) (pfe-06292025xex99.htm, filed 2025-08-05) ↗
Q1 2025Mar 30, 202553.0%-4.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-03302025xex99.htm, filed 2025-04-29) ↗
Q3 2024Sep 29, 202468.0%–Form 8-K (Earnings / Guidance Release) (pfe-9292024xex99.htm, filed 2024-10-29) ↗
Q1 2024Mar 31, 202457.0%–Form 8-K (Earnings / Guidance Release) (pfe-3312024xex99.htm, filed 2024-05-01) ↗

Cite this data

StockData. (2026). Pfizer Braftovi + Mektovi (encorafenib / binimetinib (%), quarterly Q1 2024–Q2 2026 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/braftovi-mektovi-yoy-intl

See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.